“The current circumstance has exposed some structural weaknesses during the EU’s medicines supply chain as well as a large dependence on non-EU nations for active pharmaceutical ingredients,” Kyriakides explained. She advised that supply chain problems be resolved in an EU pharmaceutical strategy expected to become released by the top with th